CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
The liver breaks down pimozide mainly through the enzymes CYP3A4 and CYP2D6. When these pathways are blocked, pimozide blood levels rise, and so does the risk of QT prolongation (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Darunavir is taken only with a booster, ritonavir or cobicistat, and in this regimen it inhibits CYP3A and CYP2D6 (darunavir SmPC, European Medicines Agency, EMA; darunavir label, US Food and Drug Administration, FDA). The pair has not been studied, but pimozide levels are expected to rise through inhibition of CYP3A, CYP2D6 and the transport protein P-glycoprotein (darunavir SmPCs, AEMPS and EMA). Antiviral protease inhibitors may markedly raise pimozide levels (pimozide SmPC, AEMPS). Pimozide prolongs the QT interval itself, and the risk of ventricular arrhythmias grows as its level rises (pimozide SmPC, AEMPS, and FDA label).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). An arrhythmia causes palpitations, dizziness and fainting. With pimozide, reports include QT prolongation, torsade de pointes, ventricular tachycardia and ventricular fibrillation (sometimes fatal), cardiac arrest and sudden death (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With too much pimozide, extrapyramidal symptoms such as muscle stiffness and restlessness (akathisia) predominate. Severe arrhythmias may occur with low blood pressure and circulatory collapse (pimozide SmPC, AEMPS). Neuroleptic malignant syndrome causes fever, generalised muscle rigidity, unstable blood pressure and pulse and altered consciousness (pimozide SmPC, AEMPS).
Management
The combination is contraindicated. Pimozide is on the contraindication list of darunavir boosted with either ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat SmPCs, European Medicines Agency, EMA; darunavir and darunavir/cobicistat labels, US Food and Drug Administration, FDA). Under both pimozide documents, pimozide must not be used with antiviral protease inhibitors, which inhibit CYP3A4. Pimozide must not be used with CYP2D6 inhibitors either: the Spanish summary of product characteristics (SmPC) rules them out as a class, and the FDA label rules out strong ones (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; pimozide FDA label). Among other neuroleptics, lurasidone, quetiapine and sertindole are contraindicated with darunavir, and perphenazine, risperidone and thioridazine may need a lower dose (darunavir SmPC, AEMPS). Do not use pimozide with other QT-prolonging drugs or in patients with low potassium or magnesium or marked bradycardia (pimozide SmPC, AEMPS). Record an electrocardiogram (ECG) before starting pimozide and repeat it during treatment. If QT prolongation, T-wave changes, U waves or arrhythmias appear, lower the pimozide dose or stop it. Stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). Correct low potassium before starting pimozide and keep potassium in the normal range throughout treatment (pimozide FDA label). In neuroleptic malignant syndrome, stop pimozide at once and start supportive treatment under close monitoring (pimozide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3